Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn molybdenum
learn TDM-105795
learn multipeptides
Research
5 / 486 resultsresearch Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
research Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells
17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.
research Cytotoxic Effect of YH239-EE and Its Enantiomer on MCF7 Cell Line
The (+) enantiomer of YH239-EE effectively kills breast cancer cells.
research Green Fabrication of ZnO Nanoparticles from Tridax procumbens leaf extract: Antimicrobial and Cytotoxic Evaluation on MCF7 and A549 Cells
Zinc oxide nanoparticles made from Tridax procumbens leaves show strong antibacterial and anticancer effects.
research In vitro anti-proliferative and antioxidant activites of chloroform extract of christia vespertilionis on mcf 7 and mda-mb-231 breast cancer cells
Christia vespertilionis extract may help fight breast cancer cells.
Community Join
5 / 1000+ resultscommunity MCL1 does anyone knows anthying about it
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
community TH07 by Triple Hair entering phase III trial
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community SUBE3 for sale in the gray market?
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.